Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/196384
Type: Artigo
Title: Comparative bioavailability of clarithromycin formulations in healthy brazilian volunteers
Author: Ruenis, A. P. D.
Moreno, R. A.
Abib-Júnior, E. B.
Simões, R. P.
Franco, L. M.
Groppo, F. C.
Baglie, S.
Franco, G. C. N.
Rosalen, P. L.
Abstract: To compare the bioavailability of clarithromycin 500 mg tablets (Merck S.A Industrias Quimicas, Sao Paulo, SP, Brazil, used as test formulation) and Klaricid (Abbott Laboratórios do Brasil Ltda, Sao Paulo, SP, Brazil, used as reference formulation) in 24 healthy volunteers. The study was conducted using an open, randomized, two-period crossover design with one-week interval between doses. Blood samples were collected at pre-dose, 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours after the administration. AUC was calculated by the trapezoidal rule extrapolation method. Cmax and tmax were compiled from the plasmatic concentration-time data. Analysis of variance was carried out using logarithmically transformed AUC(0-inf), AUC(0-24 h), Cmax and untransformed tmax. Intraindividual coefficient of variation (CV%) values were 14.25% and 12.62%, respectively for Cmax and AUC(0-24 h). The geometric mean values (+/- SD) for AUC(0-24 h) (microg x h/ml), AUC(0-inf) (microg x h/ml), and Cmax (microg/ml) for test medication were 18.56 (+/- 6.87), 18.8 (+/- 5.70) and 2.45 (+/- 0.88); the obtained values for reference medication were 18.29 (+/- 5.39), 19.10 (+/- 7.21) and 2.5 (+/- 0.69). 90% Cl for clarithromycin geometric mean of AUC(0-24 h), AUC(0-inf) and Cmax ratios (test/reference) were: 93.6-105.9%, 93.8-106.2% and 89- 103.2%. CCONCLUSION The test medication was considered bioequivalent to the reference medication based on the rate and extent of absorption.
To compare the bioavailability of clarithromycin 500 mg tablets (Merck S.A Industrias Quinnicas, Sao Paulo, SP, Brazil, used as test formulation) and Klaricid(R) (Abbott Laboratorios do Brasil Ltda, Sao Paulo, SP, Brazil, used as reference formulation) in 24 healthy Volunteers. The study was conducted using an open, randomized, two-period crossover design with one-week interval between doses. Blood samples were collected at pre-dose, 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours after the administration. AUC was calculated by the trapezoidal rule extrapolation method. C-max and t(max) were compiled from the plasmatic concentration-time data. Analysis of variance was carried out using logarithmically transformed AUC(0 - inf), AUC(0 - 24 h), C-max and untransformed t(max). Intraindividual coefficient of variation (CV%) values were 14.25% and 12.62%, respectively for C-max and AUC(0 - 24 h), The geometric mean values (+/- SD) for AUC(0 - 24 h), (mu g x h/ml), AUC(0 - inf) (mu g x b/ml), and C-max (mu g/ml) for test medication were 18.56 (+/- 6.87), 18.8 (+/- 5.70) and 2.45 (+/- 0.88); the obtained values for reference medication were 18.29 (+/- 5.39), 19. 10 (+/- 7.21) and 2.5 (+/- 0.69). 90% CI for clarithromycin geometric mean of AUC(0 - 24 h), AUC(0 - inf) and C-max ratios (test/reference) were: 93.6-105.9%, 93.8-106.2% and 89-103.2%. The test medication was considered bioequivalent to the reference medication based on the rate and extent of absorption
Subject: Farmacocinética
Equivalência terapêutica
Country: Alemanha
Editor: Dustri
Citation: International Journal Of Clinical Pharmacology And Therapeutics. v. 43, n. 8, p. 399-404, 2005-Aug.
Rights: fechado
Address: http://www.ncbi.nlm.nih.gov/pubmed/16119515
Date Issue: 2005
Appears in Collections:FOP - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
16119515.pdf218.69 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.